WO2007102286A1 - アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 - Google Patents
アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 Download PDFInfo
- Publication number
- WO2007102286A1 WO2007102286A1 PCT/JP2007/051768 JP2007051768W WO2007102286A1 WO 2007102286 A1 WO2007102286 A1 WO 2007102286A1 JP 2007051768 W JP2007051768 W JP 2007051768W WO 2007102286 A1 WO2007102286 A1 WO 2007102286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- group
- formula
- derivative
- chemical
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 37
- JWDUEKHUWWHKQO-UHFFFAOYSA-N 2-(2-aminoacetyl)pyrrolidine-1-carbonitrile Chemical class NCC(=O)C1CCCN1C#N JWDUEKHUWWHKQO-UHFFFAOYSA-N 0.000 title abstract description 4
- -1 sulfonyloxyacetylpyrrolidine Chemical class 0.000 claims abstract description 35
- 239000000126 substance Substances 0.000 claims abstract description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 7
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 6
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims abstract description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 8
- SJNAQBNIUKINQH-UHFFFAOYSA-N 2-amino-1-pyrrolidin-1-ylethanone Chemical class NCC(=O)N1CCCC1 SJNAQBNIUKINQH-UHFFFAOYSA-N 0.000 claims description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 6
- FKCMADOPPWWGNZ-YUMQZZPRSA-N [(2r)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidin-2-yl]boronic acid Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1B(O)O FKCMADOPPWWGNZ-YUMQZZPRSA-N 0.000 claims description 5
- 125000005002 aryl methyl group Chemical group 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 50
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 44
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 41
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- 239000000203 mixture Substances 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 25
- 239000013078 crystal Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 18
- 238000001914 filtration Methods 0.000 description 17
- 125000001153 fluoro group Chemical group F* 0.000 description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 125000003277 amino group Chemical group 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 9
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- 239000005457 ice water Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000001308 synthesis method Methods 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 8
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 8
- 239000012156 elution solvent Substances 0.000 description 8
- 239000002024 ethyl acetate extract Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- SWMSUNVHJSFPQX-WHFBIAKZSA-N (2s,4s)-4-fluoro-1-(2-hydroxyacetyl)pyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1C[C@H](F)CN1C(=O)CO SWMSUNVHJSFPQX-WHFBIAKZSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- HHFUFGKACHWIAV-UHFFFAOYSA-N 4-fluoropyrrolidine-2-carbonitrile Chemical compound FC1CNC(C#N)C1 HHFUFGKACHWIAV-UHFFFAOYSA-N 0.000 description 5
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 5
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical class NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000005703 Trimethylamine hydrochloride Substances 0.000 description 4
- 150000007960 acetonitrile Chemical class 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- VCLQDVVELGHZMQ-UHFFFAOYSA-N bicyclo[2.2.2]octan-4-amine Chemical compound C1CC2CCC1(N)CC2 VCLQDVVELGHZMQ-UHFFFAOYSA-N 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- SZYJELPVAFJOGJ-UHFFFAOYSA-N trimethylamine hydrochloride Chemical compound Cl.CN(C)C SZYJELPVAFJOGJ-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 3
- OTWVFHZMWFGHSJ-UHFFFAOYSA-N 1-fluoropyrrolidine Chemical compound FN1CCCC1 OTWVFHZMWFGHSJ-UHFFFAOYSA-N 0.000 description 3
- DLCLGNDBLYWYAQ-UHFFFAOYSA-N 2-(2-aminoacetyl)pyrrolidine-1-carboxamide Chemical class NCC(=O)C1CCCN1C(N)=O DLCLGNDBLYWYAQ-UHFFFAOYSA-N 0.000 description 3
- SYZRZLUNWVNNNV-UHFFFAOYSA-N 2-bromoacetyl chloride Chemical group ClC(=O)CBr SYZRZLUNWVNNNV-UHFFFAOYSA-N 0.000 description 3
- ITNWSEKOBRDGLY-UHFFFAOYSA-N 4-aminobicyclo[2.2.2]octane-1-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(N)CC2 ITNWSEKOBRDGLY-UHFFFAOYSA-N 0.000 description 3
- UMTORPRXIWIVFS-UHFFFAOYSA-N 4-fluoropyrrolidine-2-carboxamide Chemical compound NC(=O)C1CC(F)CN1 UMTORPRXIWIVFS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- HZDNNJABYXNPPV-UHFFFAOYSA-N (2-chloro-2-oxoethyl) acetate Chemical compound CC(=O)OCC(Cl)=O HZDNNJABYXNPPV-UHFFFAOYSA-N 0.000 description 2
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- AAOSLLBWWRKJIR-UHFFFAOYSA-N 2-chloro-1-pyrrolidin-1-ylethanone Chemical compound ClCC(=O)N1CCCC1 AAOSLLBWWRKJIR-UHFFFAOYSA-N 0.000 description 2
- MVEDZPQIZLYLLT-UHFFFAOYSA-N 4,4-difluoropyrrolidine-2-carboxamide Chemical compound NC(=O)C1CC(F)(F)CN1 MVEDZPQIZLYLLT-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical group C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical class NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- WASWUZRECRVZBP-BYPYZUCNSA-N (2s)-4,4-difluoro-1-(2-hydroxyacetyl)pyrrolidine-2-carboxamide Chemical compound NC(=O)[C@@H]1CC(F)(F)CN1C(=O)CO WASWUZRECRVZBP-BYPYZUCNSA-N 0.000 description 1
- GENGVAVXXMRPES-UWVGGRQHSA-N (2s,4s)-1-[2-[tert-butyl(dimethyl)silyl]oxyacetyl]-4-fluoropyrrolidine-2-carboxamide Chemical compound CC(C)(C)[Si](C)(C)OCC(=O)N1C[C@@H](F)C[C@H]1C(N)=O GENGVAVXXMRPES-UWVGGRQHSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical group C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical group C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- LNWWQYYLZVZXKS-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone Chemical compound CC(=O)N1CCCC1 LNWWQYYLZVZXKS-UHFFFAOYSA-N 0.000 description 1
- MLXDUYUQINCFFV-UHFFFAOYSA-N 2-acetyloxyacetic acid Chemical compound CC(=O)OCC(O)=O MLXDUYUQINCFFV-UHFFFAOYSA-N 0.000 description 1
- SPHXSIXITGVYAA-UHFFFAOYSA-N 2-bromo-1-pyrrolidin-1-ylethanone Chemical compound BrCC(=O)N1CCCC1 SPHXSIXITGVYAA-UHFFFAOYSA-N 0.000 description 1
- VIDRLQVNJILDEF-UHFFFAOYSA-N 2-hydroxy-1-(1h-pyrrol-2-yl)ethanone Chemical compound OCC(=O)C1=CC=CN1 VIDRLQVNJILDEF-UHFFFAOYSA-N 0.000 description 1
- RWGVUODVPQFWCJ-UHFFFAOYSA-N 2-hydroxy-1-pyrrolidin-1-ylethanone Chemical compound OCC(=O)N1CCCC1 RWGVUODVPQFWCJ-UHFFFAOYSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- KVTUSMPNLUCCQO-UHFFFAOYSA-N 3,3-difluoropyrrolidine Chemical compound FC1(F)CCNC1 KVTUSMPNLUCCQO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- SJSPAGCPICQANI-UHFFFAOYSA-N C(C)#N.CS(=O)(=O)Cl Chemical compound C(C)#N.CS(=O)(=O)Cl SJSPAGCPICQANI-UHFFFAOYSA-N 0.000 description 1
- MITOIVODJHBWEP-UHFFFAOYSA-N CC(C)C1=C(C(=NC(=C1C(C)C)C(C)C)C(C)C)C(C)C Chemical compound CC(C)C1=C(C(=NC(=C1C(C)C)C(C)C)C(C)C)C(C)C MITOIVODJHBWEP-UHFFFAOYSA-N 0.000 description 1
- ZRVIHIHTDPBEDE-UHFFFAOYSA-N CCOBO Chemical compound CCOBO ZRVIHIHTDPBEDE-UHFFFAOYSA-N 0.000 description 1
- 101100161935 Caenorhabditis elegans act-4 gene Proteins 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZKZHQHGFPKIXDH-UHFFFAOYSA-N N-(2-hydroxyacetyl)pyrrolidine-1-carboxamide Chemical class OCC(=O)NC(=O)N1CCCC1 ZKZHQHGFPKIXDH-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 101150046432 Tril gene Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- AOFRQETWYMOURE-UHFFFAOYSA-N acetonitrile benzenesulfonyl chloride Chemical compound CC#N.ClS(=O)(=O)c1ccccc1 AOFRQETWYMOURE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000005910 alkyl carbonate group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- MLWPJXZKQOPTKZ-UHFFFAOYSA-N benzenesulfonyl benzenesulfonate Chemical compound C=1C=CC=CC=1S(=O)(=O)OS(=O)(=O)C1=CC=CC=C1 MLWPJXZKQOPTKZ-UHFFFAOYSA-N 0.000 description 1
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical group C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- XQPRBTXUXXVTKB-UHFFFAOYSA-M caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- DMQSHEKGGUOYJS-UHFFFAOYSA-N n,n,n',n'-tetramethylpropane-1,3-diamine Chemical compound CN(C)CCCN(C)C DMQSHEKGGUOYJS-UHFFFAOYSA-N 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- HIWSQDSADMHZNP-UHFFFAOYSA-N oxolane;(2,2,2-trifluoroacetyl) 2,2,2-trifluoroacetate Chemical compound C1CCOC1.FC(F)(F)C(=O)OC(=O)C(F)(F)F HIWSQDSADMHZNP-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical group C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 perazine Drugs 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical class N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titanium dioxide Inorganic materials O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to aminoacetylpyrrolidine carbo-tolyl having dipeptidyl peptidase IV (DPP-IV) inhibitory activity and useful for the prevention and Z or treatment of DPP-IV-related diseases such as type II diabetes
- DPP-IV dipeptidyl peptidase IV
- the present invention relates to a method for producing a derivative and a production intermediate thereof.
- DPP-IV dipeptidyl peptidase IV
- type II diabetes dipeptidyl peptidase IV
- derivatives having DPP-IV inhibitory activity have been reported. Being sung.
- aminoacetylpyrrolidinecarbo-tolyl derivatives have an excellent blood glucose lowering action, and thus many promising compounds have been reported as antidiabetic drugs (Non-patent Documents 1 to 2 and Patent Documents 1 to 16).
- the present applicant has disclosed a compound represented by the following structural formula (formula 4) as an aminoacetylpyrrolidinecarbonitryl derivative (Patent Document 9).
- R3 is an optionally substituted C-C alkyl group, optionally substituted C-C
- An aromatic heterocycle, or substituted, may be an aliphatic heterocycle; n represents 1 or 2; )
- the derivative shown in Formula 4 is derived from 1 (2 chloroacetyl) pyrrolidine 2 carbo-tolyl Or 1 (2-bromoacetyl) pyrrolidine 2-carbo-tolyl derivative and the corresponding amine in the presence of a base (Patent Document 9).
- the 1- (2-chloroacetyl) pyrrolidine-2-carbo-tolyl derivative used in the raw material is the 1- (2-bromoacetyl) pyrrolidine-2-carbo-tolyl derivative is bromoacetyl chloride or chloroacetyl. It is produced by the reaction of chloride and pyrrolidine derivatives (Patent Documents 1 to 9).
- Patent Documents 14 to 17 As a synthesis method without using bromoacetyl chloride or chloroacetyl chloride, a method using a sulfo-loxycetylpyrrolidine derivative is conceivable. Sulfo-loxycetylpyrrolidine derivatives have already been disclosed as general concepts (Patent Documents 14 to 17). In addition, it is described that 1- (2 methanesulfonoxyloxycetyl) pyrrolidine 2 carbonitryl derivative and 1- (2-toluenesulfooxyxacetyl) pyrrolidine-2-carbo-tolyl derivative can be used (Patent Documents 10 to 10). 13).
- Non-Patent Document 1 Journal of Medicinal Chemistry, 46 ⁇ , 2774 (2003)
- Non-Patent Document 2 Bioorganic & Medicinal Chemistry, 12 ⁇ , p. 6053 (2004) Patent Document 1: Special Table 2000-511559
- Patent Document 2 Japanese Patent Publication No. 2002-531547
- Patent Document 3 JP 2002-356471 A
- Patent Literature 4 Japanese Translation of Special Publication 2004-500321
- Patent Document 5 Special Table 2005-529078
- Patent Literature 6 Special Publication 2004-503531
- Patent Document 7 US 2002/019339
- Patent Document 8 WO04 / 099185 non-fret
- Patent Document 9 WO 05/075421 Nonfret
- Patent Document 10 WO 02/38541 Nonfret
- Patent Document ll WO 03/095425 Pamphlet
- Patent Document 12 Japanese Patent Application Laid-Open No. 2004-26820
- Patent Document 13 Japanese Unexamined Patent Application Publication No. 2006-160733
- Patent Document 14 Japanese Patent Application Laid-Open No. 2002-356472
- Patent Document 15 JP 2004-2367 A
- Patent Document 16 Japanese Patent Application Laid-Open No. 2004-2368
- Patent Document 17 WO 04/009544 Pamphlet
- the problem to be solved by the present invention is a method for safely and efficiently producing an aminoacetylpyrrolidinecarbo-tolyl derivative represented by the formula 4, which is useful as a DPP-IV inhibitor, and a novel production intermediate. It is in providing the body.
- the present invention relates to
- R1 is an optionally substituted C to C alkyl group, optionally substituted C to C
- X represents CH, CHF or CF.
- a sulfo-loxyacetyl pyrrolidine derivative according to (1) characterized in that it is a benzenesulfo-loxyacetyl pyrrolidine derivative represented by the formula:
- R1 is an optionally substituted C to C alkyl group, optionally substituted C to C
- R3 is an optionally substituted C to C alkyl group, optionally substituted C
- n 1 or 2.
- X represents CH, CHF or CF.
- R3 is an optionally substituted C to C alkyl group, optionally substituted C
- n 1 or 2.
- substituted and optionally substituted C to C alkyl group is halogen
- Group which may contain 1 to 3 heteroatoms, 4 to 9-membered cyclic amino group, formylamino group, C to C alkylcarbolumino group, C to C alkoxycarbolamino group
- substituted and optionally a C to C cycloalkyl group refers to ha.
- 1 c alkoxy group may be substituted 6
- a C to C group optionally having 1 to 5 substituents selected from, for example, a ru-lamino group
- a chloroalkyl group such as a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, or a cyclohexyl group.
- the "optionally substituted aryl group" represented in the present specification means a halogen atom, an optionally substituted C to C alkyl group, a hydroxyl group, a cyano group, a nitro group,
- Amino group and substituted may be aryl, sulfo-lamino group, etc., may have 1-5 selected substituents, may be aryl methyl group (phenylmethyl group, naphthylmethyl group, pyridylmethyl group) Group, quinolylmethyl group or indolylmethyl group).
- substituted or arylethyl group represented in the present specification means a halogen atom, an optionally substituted C to C alkyl group, a hydroxyl group, a cyano group, a nitro group.
- An amino group and a substituted group may have 1 to 5 selected substituents such as an arylsulfo-lumino group, and may have an aryl group (a phenylethyl group, a naphthylethyl group, a pyridylethyl group). Quinolylethyl group or indolylethyl group).
- the "optionally substituted aromatic hydrocarbon” represented in the present specification is a halogen atom, a hydroxyl group, a cyano group, a nitro group, or an optionally substituted C to C alkyl.
- aromatic hydrocarbon such as a benzene ring, a naphthalene ring or an anthracene ring
- substituted and optionally aromatic heterocycle means a halogen atom, a hydroxyl group, a cyano group, a nitro group, a C to C alkyl group, C to C C alkoxy group
- a good aromatic heterocycle (a 5- or 6-membered aromatic monocyclic heterocycle containing 1 to 3 heteroatoms arbitrarily selected from nitrogen, oxygen and sulfur atoms, 9-membered or 10-membered aromatic condensed heterocycle, such as pyridine ring, pyrimidine ring, pyridazine ring, triazine Ring, quinoline ring, naphthyridine ring, quinazoline ring, quinazoline ring, atalidine ring, pyrrole ring, furan ring, thiophene ring, imidazole ring, pyrazole ring, oxazole ring, isoxazole ring, thiazole ring, indole ring, benzofuran ring, benzothiazole ring, benzimidazo A ring of benzene or a benzoxazole ring).
- Substituted or aliphatic heterocycle represented in the present specification means a halogen atom, a C to C alkyl group, a hydroxyl group, a cyano group, a nitro group, a C to C C alkoxy group
- C to C alkylthio groups, etc. may have 1 to 5 selected substituents
- Aliphatic heterocycle (optionally selected from nitrogen, oxygen, and sulfur atoms
- Bicycloesteramine derivative or salt thereof represented by the present specification may be any salt as long as it is acceptable as an amine salt, but preferably is hydrochloric acid. Salt, hydrobromide, hydroiodide; sulfonate such as methanesulfonate, tosylate, benzenesulfonate; acetate, trifluoroacetate, malonate, succinate, maleate Carboxylates such as acids; sulfates.
- halogen atom represented in the present specification means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- a method for producing an aminoacetylpyrrolidinecarbonitryl derivative represented by the formula 4 (wherein X and R3 are the same as described above) via a 1 (2-benzenesulfo-oxyxethyl) pyrrolidine derivative is as follows. (Scheme 1).
- Steps 1 and 2 are those in which a 1 (2 hydroxyacetyl) pyrrolidinecarboxamide derivative represented by formula 5 (wherein X is the same as above) is benzenesulfonated to give formula 6 (where X is (Same as the above) 1) (2-Benzenesulfo-loxycetyl) pyrrolidinecarboxamide derivative represented by formula (7) is prepared, and further subjected to dehydration reaction, whereby the compound is represented by the formula 7 1- (2-benzenesulfo-loxycetyl) pyrrolidinecarbo-tolyl derivative.
- benzene sulfonating agent used for the benzene sulfonation in Step 1 benzenesulfuryl chloride, benzenesulfonic anhydride, or the like is preferable.
- an alkali carbonate such as sodium hydrogen carbonate or potassium carbonate, triethylamine, diisopropylethylamine, N-methylmorpholine, N, N, N, N, N Tetramethylethylenediamine, N, N, N, N, monotetramethyl-1,3 propanediamine, diazabicyclo [5.4.0] —7 undecene, pyridine, 4-dimethylaminoviridine or 1,8 bis (dimethylamino) naphthalene And, preferably, triethylamine, N, N, N ′, N′-tetramethyl-1,3 propanediamine or a mixture thereof can be used. Further, trimethylamine hydrochloride can be added as an additive to the reaction solution.
- Examples of the dehydrating agent used in the dehydration reaction in Step 2 include diphosphorus pentoxide, phosphorus pentachloride, phosphorus oxychloride, thiochloride, oxalyl chloride, p-toluenesulfonyl chloride, methanesulfonyl chloride, Chlorosulfyl isocyanate, N, N'-dicyclohexylcarbodiimi And trifluoroacetic anhydride, and preferably oxalyl chloride or trifluoroacetic anhydride. These dehydrating agents are added by themselves or as a solution dissolved in an appropriate solvent.
- an alkali carbonate such as sodium hydrogen carbonate or potassium carbonate, triethylamine, diisopropylethylamine, N-methylmorpholine, N, N, N, N, monotetramethylethylene Diamine, N, N, N, N, monotetramethyl-1,3 propanediamine, diazabicyclo [5.4.0] —7-undecene, pyridine, 4 dimethylaminopyridine or 1,8 bis (dimethylamino) naphthalene
- tertiary amines such as
- an inert solvent which does not participate in the reaction for example, tetrahydrofuran, dioxane, ethyl ether, dimethoxyethane, acetonitrile, ethyl acetate, toluene, xylene, dichloromethane, chloroform, 1, 2— Dichloroethane ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ dimethylacetamide, ⁇ -methyl-2-pyrrolidone, dimethyl sulfoxide and the like are used, preferably tetrahydrofuran, dichloromethane or acetonitrile.
- Each reaction can be carried out at ⁇ 78 to 150 ° C., preferably ⁇ 40 ° C. to 25 ° C., more preferably 20 ° C. to 15 ° C.
- Steps 1 and 2 1 (2-benzenesulfo-loxycetyl) pyrrolidinecarboxamide derivative represented by Formula 6 (wherein X is the same as described above) generated in Step 1 is isolated.
- the next step 2 may be performed instead.
- step 3 1 (2 benzenesulfo-loxycetyl) pyrrolidinecarbo-tolyl derivative represented by formula 7 (wherein X is the same as defined above) in the presence or absence of a base,
- an amine derivative represented by the formula 3 wherein R3 is the same as above
- an aminoacetylpyrrolidinecarbo-tolyl represented by the formula 4 wherein X and R3 are the same as above.
- an alkali carbonate such as sodium hydrogen carbonate, potassium carbonate or cesium carbonate, triethylamine, diisopropylethylamine, N-methylmorpholine, diazabicyclo [5.4.0] — Tertiary amines such as 7undecene, pyridine, 4-dimethylaminopyridine, 1,8 bis (dimethylamino) naphthalene, phosphazene base or pentaisopropyl pyridine, preferably using potassium carbonate Can do.
- tetraptyl ammonium bromide When a catalyst is used in this reaction, tetraptyl ammonium bromide, tetrabutyl ammonium chloride, benzyltriethyl ammonium bromide, odorous lithium, lithium iodide, sodium iodide, potassium bromide, potassium iodide, odor Examples thereof include phase transfer catalysts such as cesium iodide and yowi ⁇ cesium or inorganic salts, and potassium iodide can be preferably used.
- an inert solvent not involved in the reaction for example, acetone, ethanol, tetrahydrofuran, dioxane, ethyl ether, dimethetetane, acetonitrile, ethyl acetate, toluene, xylene, dichloromethane, chloroform, 1,2 -Dichloroethane, ⁇ , ⁇ -dimethylformamide, ⁇ , ⁇ -dimethylacetamide, ⁇ -methyl-2-pyrrolidone, dimethyl sulfoxide and the like are used, and preferably ⁇ , ⁇ -dimethylformamide can be used.
- This condensation reaction can be carried out at ⁇ 30 to 150 ° C., preferably 0 ° C. to 80 ° C.
- sulfo-loxycetylpyrrolidinecarbo-tolyl derivatives can be synthesized in the same manner as in Step 1 and Step 2 using the corresponding sulfonylating agent. It can be used in the production of aminoacetylpyrrolidinecarbo-tolyl derivatives by the same method.
- aminoacetylpyrrolidinecarbo-tolyl derivative represented by the formula 4 (wherein X and R3 are as defined above) can also be produced by the following production method (Scheme 2).
- step 1 According to the production method shown in scheme 1 (step 1), it is represented by formula 6 (wherein X is the same as defined above). 1 (2-benzenesulfo-loxycetyl) pyrrolidinecarboxamide derivative is prepared and then reacted with an amine derivative represented by formula 3 (wherein R3 is the same as above) to give formula 8 (wherein X,
- the aminoacetylpyrrolidinecarboxamide derivative represented by) can be produced (step 4). Further, by dehydrating the aminoacetylpyrrolidinecarboxamide derivative represented by the formula 8 (wherein X and R3 are the same as above), the formula 4 (wherein X and R3 are the same as above) is dehydrated. The aminoacetylpyrrolidinecarbo-tolyl derivative represented can be prepared (step 5).
- step 4 can be performed by the same method as step 3, and step 5 can be performed by the same method as step 2.
- other sulfo-loxyacetyl pyrrolidine strength lupo-tolyl derivatives can be synthesized by the same method as in Step 1 using the corresponding sulfonylating agent.
- R3 is the same as above. It can be used for the production of aminoacetylpyrrolidinecarboxamide derivatives represented by
- Corrosive liquid reagents such as promoacetyl chloride and chloroacetyl chloride may be difficult to handle for industrial use. These compounds are unstable and react violently with water to generate corrosive gases such as hydrogen chloride. Furthermore, it is highly toxic to the human body, causing burns by contact and pulmonary edema by inhalation. According to this production method, amino acid useful as a DPP-IV inhibitor does not use chloroacetyl chloride promoacetylpromide but via a 1 (2-benzenesulfo-oxyxethyl) pyrrolidine derivative as a reaction intermediate. An acetylpyrrolidine carbo-tolyl derivative can be produced more safely.
- the 1 (2 benzenesulfo-oxyxetyl) pyrrolidine carbo-tolyl derivative disclosed in the present invention has sufficient reactivity in the reaction with various amines, but particularly with the bicycloesteramine derivative.
- the yield is high and is particularly useful for the production of a DPP-IV inhibitor which is a bicycloester derivative represented by the formula 4.
- Method B (2S, 4S) -4 fluoropyrrolidine-2-strong rubonic acid methyl hydrochloride (1.84 g) was suspended in dehydrated acetonitrile (37 mL) and cooled on an ice-water bath while diisopropyl ether. After dropwise addition of tyramine (1.83 mL), the mixture was further stirred for 15 minutes. To the reaction mixture was prepared 1-hydroxybenzotriazole (0.46 g), acetooxyacetic acid (1.30 g), and 3-ethyl-1- (3-dimethylaminopropyl) carpositimide hydrochloride (2. 30 g), and then at room temperature. The mixture was stirred for 4 hours and further left overnight.
- the reaction mixture was concentrated under reduced pressure, the residue was dissolved in ethyl acetate (150 mL), and washed successively with water (20 mL), saturated aqueous sodium hydrogen carbonate solution (20 mL), and saturated brine (20 mL). All the washings were combined, salted up to saturation, and extracted with ethyl acetate (100 mL ⁇ 2). All the ethyl acetate extracts were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was dissolved in methanol saturated with ammonia (30 mL) and then stirred at room temperature for 4 hours.
- (2S) 4,4-Difluoropyrrolidine-2-methyl rubonic acid hydrochloride (1.61 g) was suspended in dehydrated acetonitrile (25 mL), and triethylamine (2.50 mL) was added while cooling on an ice-water bath. After dropwise addition, the mixture was further stirred for 15 minutes. Acetoxyacetyl chloride (0.91 mL) was then added dropwise to the reaction mixture at the same temperature, and the mixture was further stirred for 1 hour. Insoluble matters in the reaction mixture were removed by filtration, and the filtrate was concentrated under reduced pressure.
- the reaction mixture was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (400 mL).
- the ethyl acetate solution was washed with water (50 mL), saturated aqueous sodium hydrogen carbonate solution (50 mL) and saturated brine (50 mL) in this order, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- (2S) -4,4-Difluoro-1 (2 hydroxyacetyl) pyrrolidine-2 carboxamide (1.66 g) suspended in acetonitrile (40 mL), N, N, N, N, -tetramethyl 1,3-propanediamine (133 L) and triethylamine (2.20 mL) were added, and then benzenesulfur chloride (1.20 mL) was added dropwise while cooling on a salt-ice bath. After stirring at the same temperature for 1 hour, saturated brine (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (2 ⁇ 80 mL).
- (2S, 4S) 4 Fluoro-1 (2 hydroxyacetyl) pyrrolidine-2 carboxamide (381 mg) is suspended in acetonitrile, and N, N, N, N, -tetramethyl-1,3 pronodiamine (34.0 L ) And triethylamine (0.98 mL) were added, and benzenesulfuryl chloride (0.28 mL) was added dropwise while cooling on a salt-ice bath. After stirring at the same temperature for 1 hour, trifluoroacetic anhydride (0.34 mL) was added dropwise, and the mixture was further stirred for 1 hour.
- Table 1 shows 1- (2-bromoacetyl) pyrrolidine-2-carbo-tolyl derivative (Comparative Example 1), 1- (2-chloroacetyl) pyrrolidine 2-carbo-tolyl derivative (Comparative Example 2) or 1- ( The production ratio of trialkyl derivatives when 2-benzenesulfonyloxycetyl) pyrrolidinecarbo-tolyl derivative (Reference Example 6) was used is shown.
- UV absorptiometer (measurement wavelength: 205 nm)
- Example 1 Benzenesulfonyl Chloride Acetonitrile -151: C 6 H 3 80 Comparative Example 3 Methanesulfonyl Chloride Acetonitrile -15 with CH 3 -Comparative Example 4 Toluenesulfonyl Chloride Acetonitrile -1st: 4 -CH 3 -C 6 H 4 48
- the process of sulfoniol can be obtained in a high yield (Example 1), and the corresponding 1 (2-benzenesulfo-loxycetyl) pyrrolidinecarbo-tolyl derivative is also available. Obtained in high yield. The yield was further improved when the next dehydration step was carried out without isolating the 1- (2-benzenesulfo-loxycetyl) pyrrolidinecarboxamide derivative (Examples 4 and 5). From the above results, it was confirmed that the production method of the present invention is particularly efficient when a benzenesulfo-loxycetylpyrrolidine carbo-tolyl derivative is used.
- the present invention relates to a novel production intermediate, a benzenesulfo-loxypyrrolidine derivative, and a derivative thereof. It relates to the manufacturing method. According to the present invention, the use of chloroacetyl chloride or the like can be avoided, and a safe and efficient method for producing an aminoacetylcyanopyrrolidine derivative represented by Formula 4 can be provided, which is industrially useful.
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007224066A AU2007224066B2 (en) | 2006-03-08 | 2007-02-02 | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
CN2007800077961A CN101395131B (zh) | 2006-03-08 | 2007-02-02 | 氨基乙酰基吡咯烷甲腈衍生物的制备方法及其制备中间体 |
EP07707942A EP1995237A4 (en) | 2006-03-08 | 2007-02-02 | PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF |
CA2645154A CA2645154C (en) | 2006-03-08 | 2007-02-02 | Method for producing aminoacetylpyrrolidinecarbonitrile derivative and production intermediate thereof |
US12/224,849 US7915427B2 (en) | 2006-03-08 | 2007-02-02 | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
JP2008503761A JP5101489B2 (ja) | 2006-03-08 | 2007-02-02 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
KR1020087023532A KR101216965B1 (ko) | 2006-03-08 | 2008-09-26 | 아미노아세틸피롤리딘카르보니트릴 유도체의 제조방법 및 그 제조 중간체 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-062548 | 2006-03-08 | ||
JP2006062548 | 2006-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007102286A1 true WO2007102286A1 (ja) | 2007-09-13 |
Family
ID=38474728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/051768 WO2007102286A1 (ja) | 2006-03-08 | 2007-02-02 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7915427B2 (ja) |
EP (1) | EP1995237A4 (ja) |
JP (1) | JP5101489B2 (ja) |
KR (1) | KR101216965B1 (ja) |
CN (1) | CN101395131B (ja) |
AU (1) | AU2007224066B2 (ja) |
CA (1) | CA2645154C (ja) |
WO (1) | WO2007102286A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010032723A1 (ja) | 2008-09-16 | 2010-03-25 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の精製方法およびその塩 |
US7754757B2 (en) | 2004-02-05 | 2010-07-13 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
US8143427B2 (en) | 2007-03-22 | 2012-03-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
WO2013011887A1 (ja) * | 2011-07-19 | 2013-01-24 | セントラル硝子株式会社 | (2s,4s)-1-ヒドロキシアセチル-2-アミノカルボニル-4-フルオロピロリジンの製造方法 |
US8476470B2 (en) | 2008-08-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102186474A (zh) * | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | 稳定的医药组合物 |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000511559A (ja) | 1996-11-07 | 2000-09-05 | ノバルティス アクチエンゲゼルシャフト | N―置換2―シアノピロリジン |
US20020019339A1 (en) | 1995-06-06 | 2002-02-14 | Advanced Tissue Sciences, Inc. | Compositions and methods for production and use of an injectable naturally secreted extracellular matrix |
WO2002038541A1 (fr) | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Derives de cyanopyrrolidine |
JP2002531547A (ja) | 1998-12-10 | 2002-09-24 | ノバルティス アクチエンゲゼルシャフト | N置換されている2−シアノピロリジン |
JP2002356472A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 含窒素五員環化合物 |
JP2002356471A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
WO2003095425A1 (fr) | 2002-05-09 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Derives de cyanopyrrolidine |
JP2004500321A (ja) | 1999-03-19 | 2004-01-08 | アノーメッド インコーポレイティド | 金属錯体を含む薬学的組成物 |
JP2004002368A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JP2004002367A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
WO2004009544A1 (ja) | 2002-07-23 | 2004-01-29 | Yamanouchi Pharmaceutical Co., Ltd. | 2-シアノ−4−フルオロピロリジン誘導体又はその塩 |
JP2004503531A (ja) | 2000-06-13 | 2004-02-05 | ノバルティス アクチエンゲゼルシャフト | 2−シアノピロリジン誘導体および薬剤としてのそれらの使用 |
WO2004099185A1 (en) | 2003-05-09 | 2004-11-18 | Fujisawa Pharmaceutical Co. Ltd. | 2-cyanopyrrolidine derivatives and their use as dpp-iv inhibitors |
WO2005075421A1 (ja) | 2004-02-05 | 2005-08-18 | Kyorin Pharmaceutical Co., Ltd. | ビシクロエステル誘導体 |
JP2005529078A (ja) | 2002-03-06 | 2005-09-29 | サノフィ−アベンティス | N−アミノアセチル−ピロリジン−2−カルボニトリルおよびddp−iv阻害剤としてのその使用 |
JP2006160733A (ja) | 2004-11-15 | 2006-06-22 | Taisho Pharmaceut Co Ltd | シアノフルオロピロリジン誘導体を有効成分として含有する医薬 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US5965764A (en) * | 1997-08-06 | 1999-10-12 | Toray Industries, Inc. | Process for producing a nitrile |
JPH11322701A (ja) | 1997-08-06 | 1999-11-24 | Toray Ind Inc | ニトリルの製造方法 |
US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
US20040152745A1 (en) * | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
WO2001034594A1 (en) | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
US6380398B2 (en) * | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
EP1254113A1 (en) | 2000-01-24 | 2002-11-06 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
US7064145B2 (en) * | 2000-02-25 | 2006-06-20 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6432969B1 (en) * | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
EP1950199B1 (en) | 2000-08-10 | 2009-12-02 | Mitsubishi Tanabe Pharma Corporation | Proline derivatives and use thereof as drugs |
US20020037829A1 (en) * | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
KR100526091B1 (ko) * | 2000-10-06 | 2005-11-08 | 다나베 세이야꾸 가부시키가이샤 | 지방족 질소 함유 오원환 화합물 |
PL364221A1 (en) * | 2001-02-02 | 2004-12-13 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
CA2450579A1 (en) * | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
IL158923A0 (en) * | 2001-06-27 | 2004-05-12 | Smithkline Beecham Corp | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
JP4300108B2 (ja) * | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
AU2002360732A1 (en) * | 2001-12-26 | 2003-07-24 | Guilford Pharmaceuticals | Change inhibitors of dipeptidyl peptidase iv |
WO2003080633A1 (en) * | 2002-03-25 | 2003-10-02 | Nippon Kayaku Kabushiki Kaisha | Novel $g(a)-amino-n-(diaminophosphinyl)lactam derivative |
US20040106802A1 (en) * | 2002-04-08 | 2004-06-03 | Torrent Pharmaceuticals Ltd. | Novel compounds and therapeutic uses thereof |
CN1633420A (zh) * | 2002-04-08 | 2005-06-29 | 托伦脱药品有限公司 | 噻唑烷-4-腈和类似物以及它们作为二肽基-肽酶抑制剂的用途 |
HUP0202001A2 (hu) * | 2002-06-14 | 2005-08-29 | Sanofi-Aventis | DDP-IV gátló hatású azabiciklooktán- és nonánszármazékok |
WO2004007446A1 (ja) | 2002-07-10 | 2004-01-22 | Yamanouchi Pharmaceutical Co., Ltd. | 新規なアゼチジン誘導体又はその塩 |
US20040017848A1 (en) * | 2002-07-25 | 2004-01-29 | Adc Dsl Systems, Inc. | High-speed digital subscriber line (HDSL) wander reduction |
US20040121964A1 (en) * | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
KR101072236B1 (ko) | 2002-09-19 | 2011-10-12 | 아보트 러보러터리즈 | 디펩티딜 펩티다제-iv(dpp-iv)의 억제제로서의약제학적 조성물 |
PT1715893E (pt) | 2004-01-20 | 2009-10-20 | Novartis Pharma Ag | Formulação para compressão directa e processos |
EP1717225A4 (en) | 2004-02-18 | 2009-10-21 | Kyorin Seiyaku Kk | BICYCLIC AMIDE DERIVATIVES |
EP1719757B1 (en) * | 2004-02-27 | 2013-10-09 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
TWI354569B (en) | 2004-05-28 | 2011-12-21 | Bristol Myers Squibb Co | Coated tablet formulation and method |
PE20060652A1 (es) | 2004-08-27 | 2006-08-11 | Novartis Ag | Composiciones farmaceuticas de liberacion inmediata que comprenden granulos de fusion |
EA013463B1 (ru) | 2004-10-12 | 2010-04-30 | ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. | Новые ингибиторы дипептидилпептидазы iv, содержащие их фармацевтические композиции, способ их получения и способ лечения с их применением |
JP2008019168A (ja) | 2004-10-22 | 2008-01-31 | Astellas Pharma Inc | 2−シアノ−4−フルオロピロリジン誘導体の製造法 |
GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
DE102005019572A1 (de) * | 2005-04-27 | 2006-11-09 | Siemens Ag | Verfahren zur Auswertung und Darstellung von Röntgenprojektionsbildern und Röntgendurchsichtgerät |
MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
JP2010120851A (ja) | 2007-02-09 | 2010-06-03 | Kyorin Pharmaceut Co Ltd | 二量化シクロ誘導体 |
JPWO2008114857A1 (ja) * | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
JP2008239543A (ja) | 2007-03-27 | 2008-10-09 | Kyorin Pharmaceut Co Ltd | ビシクロアミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
JP2008290969A (ja) | 2007-05-24 | 2008-12-04 | Kyorin Pharmaceut Co Ltd | アミノアセチルピロリジン誘導体の製造方法 |
JP2009114127A (ja) | 2007-11-07 | 2009-05-28 | Kyorin Pharmaceut Co Ltd | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
CA2732984A1 (en) | 2008-08-07 | 2010-02-11 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
CN102186474A (zh) | 2008-08-14 | 2011-09-14 | 杏林制药株式会社 | 稳定的医药组合物 |
JP2010070454A (ja) | 2008-09-16 | 2010-04-02 | Kyorin Pharmaceut Co Ltd | アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 |
US20110172444A1 (en) | 2008-09-16 | 2011-07-14 | Futoshi Shiga | Method for purifying aminoacetylpyrrolidinecarbonitrile derivative and salt thereof |
-
2007
- 2007-02-02 CN CN2007800077961A patent/CN101395131B/zh not_active Expired - Fee Related
- 2007-02-02 AU AU2007224066A patent/AU2007224066B2/en not_active Ceased
- 2007-02-02 WO PCT/JP2007/051768 patent/WO2007102286A1/ja active Application Filing
- 2007-02-02 JP JP2008503761A patent/JP5101489B2/ja not_active Expired - Fee Related
- 2007-02-02 EP EP07707942A patent/EP1995237A4/en not_active Withdrawn
- 2007-02-02 CA CA2645154A patent/CA2645154C/en not_active Expired - Fee Related
- 2007-02-02 US US12/224,849 patent/US7915427B2/en not_active Expired - Fee Related
-
2008
- 2008-09-26 KR KR1020087023532A patent/KR101216965B1/ko not_active IP Right Cessation
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020019339A1 (en) | 1995-06-06 | 2002-02-14 | Advanced Tissue Sciences, Inc. | Compositions and methods for production and use of an injectable naturally secreted extracellular matrix |
JP2000511559A (ja) | 1996-11-07 | 2000-09-05 | ノバルティス アクチエンゲゼルシャフト | N―置換2―シアノピロリジン |
JP2002531547A (ja) | 1998-12-10 | 2002-09-24 | ノバルティス アクチエンゲゼルシャフト | N置換されている2−シアノピロリジン |
JP2004500321A (ja) | 1999-03-19 | 2004-01-08 | アノーメッド インコーポレイティド | 金属錯体を含む薬学的組成物 |
JP2004503531A (ja) | 2000-06-13 | 2004-02-05 | ノバルティス アクチエンゲゼルシャフト | 2−シアノピロリジン誘導体および薬剤としてのそれらの使用 |
JP2002356472A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 含窒素五員環化合物 |
JP2002356471A (ja) | 2000-10-06 | 2002-12-13 | Tanabe Seiyaku Co Ltd | 脂肪族含窒素五員環化合物 |
WO2002038541A1 (fr) | 2000-11-10 | 2002-05-16 | Taisho Pharmaceutical Co., Ltd. | Derives de cyanopyrrolidine |
JP2005529078A (ja) | 2002-03-06 | 2005-09-29 | サノフィ−アベンティス | N−アミノアセチル−ピロリジン−2−カルボニトリルおよびddp−iv阻害剤としてのその使用 |
JP2004002368A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
JP2004002367A (ja) | 2002-04-04 | 2004-01-08 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
WO2003095425A1 (fr) | 2002-05-09 | 2003-11-20 | Taisho Pharmaceutical Co.,Ltd. | Derives de cyanopyrrolidine |
JP2004026820A (ja) | 2002-05-09 | 2004-01-29 | Taisho Pharmaceut Co Ltd | ジペプチジルペプチダーゼiv阻害剤 |
WO2004009544A1 (ja) | 2002-07-23 | 2004-01-29 | Yamanouchi Pharmaceutical Co., Ltd. | 2-シアノ−4−フルオロピロリジン誘導体又はその塩 |
WO2004099185A1 (en) | 2003-05-09 | 2004-11-18 | Fujisawa Pharmaceutical Co. Ltd. | 2-cyanopyrrolidine derivatives and their use as dpp-iv inhibitors |
WO2005075421A1 (ja) | 2004-02-05 | 2005-08-18 | Kyorin Pharmaceutical Co., Ltd. | ビシクロエステル誘導体 |
JP2006160733A (ja) | 2004-11-15 | 2006-06-22 | Taisho Pharmaceut Co Ltd | シアノフルオロピロリジン誘導体を有効成分として含有する医薬 |
Non-Patent Citations (3)
Title |
---|
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 6053 |
JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, 2003, pages 2774 |
See also references of EP1995237A4 |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754757B2 (en) | 2004-02-05 | 2010-07-13 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
US8053465B2 (en) | 2004-02-05 | 2011-11-08 | Kyorin Pharmaceutical Co., Ltd. | Bicycloester derivative |
US8143427B2 (en) | 2007-03-22 | 2012-03-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
US8476470B2 (en) | 2008-08-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
WO2010032723A1 (ja) | 2008-09-16 | 2010-03-25 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の精製方法およびその塩 |
EP2332908A1 (en) * | 2008-09-16 | 2011-06-15 | Kyorin Pharmaceutical Co., Ltd. | Method for purifying aminoacetylpyrrolidinecarbonitrile derivative and salt thereof |
EP2332908A4 (en) * | 2008-09-16 | 2012-02-29 | Kyorin Seiyaku Kk | METHOD FOR CLEANING AN AMINOACETYLPYRROLIDINE CARBONITRILE DERIVATIVE AND SALT THEREFOR |
WO2013011887A1 (ja) * | 2011-07-19 | 2013-01-24 | セントラル硝子株式会社 | (2s,4s)-1-ヒドロキシアセチル-2-アミノカルボニル-4-フルオロピロリジンの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1995237A4 (en) | 2011-07-06 |
CA2645154A1 (en) | 2007-09-13 |
KR20080099865A (ko) | 2008-11-13 |
KR101216965B1 (ko) | 2012-12-31 |
EP1995237A1 (en) | 2008-11-26 |
AU2007224066A1 (en) | 2007-09-13 |
JP5101489B2 (ja) | 2012-12-19 |
CA2645154C (en) | 2011-11-29 |
US7915427B2 (en) | 2011-03-29 |
US20090048454A1 (en) | 2009-02-19 |
CN101395131A (zh) | 2009-03-25 |
JPWO2007102286A1 (ja) | 2009-07-23 |
AU2007224066B2 (en) | 2011-10-27 |
CN101395131B (zh) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2123636B1 (en) | Method for producing aminoacetylpyrrolidinecarbonitrile derivative | |
AU2012351748B2 (en) | Substituted pyrazolo[1,5-a] pyridine as tropomyosin receptor kinase (Trk) inhibitors | |
CN106470975B (zh) | 多环氨基甲酰基吡啶酮化合物的合成 | |
WO2007102286A1 (ja) | アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 | |
KR20180081535A (ko) | 포스포디에스테라제 억제제로서 2-페닐-3,4-디하이드로피롤로[2,1-f][1,2,4]트리아지논 유도체 및 이의 용도 | |
JP6574474B2 (ja) | キラルジペプチジルペプチダーゼ−iv阻害剤の製造方法 | |
JP4476810B2 (ja) | 化学中間体 | |
JP2009114127A (ja) | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 | |
KR101143073B1 (ko) | Glyt-1 억제제의 합성 방법 | |
JP2008290969A (ja) | アミノアセチルピロリジン誘導体の製造方法 | |
EP2882752A1 (en) | Process for the preparation of sitagliptin and intermediate compounds | |
JP2022500433A (ja) | Betブロモドメイン阻害剤の固体形態の製造方法 | |
JPWO2010032723A1 (ja) | アミノアセチルピロリジンカルボニトリル誘導体の精製方法およびその塩 | |
JP4368304B2 (ja) | アミノ−ピロリジン誘導体を製造するための方法 | |
US20050282804A1 (en) | Process for preparing 10alpha-[4'-(S,S-dioxothiomorpholin-1'-yl)]-10-deoxo-10-dihydroartemisinin | |
TW201625632A (zh) | Pi3k抑制劑及其鹽之合成 | |
JP2010070454A (ja) | アミノアセチルピロリジンカルボニトリル誘導体の製造方法およびその製造中間体 | |
CA3214802A1 (en) | Processes for making bicyclic ketone compounds | |
WO2020138015A1 (ja) | ピラゾロ[1,5-a]ピリミジン大環状化合物 | |
Hendriks | Syntheses, modifications and biological applications of sulfoximines and aromatic pentafluorosulfanyl compounds | |
JP2021516665A (ja) | 2−クロロ−4−ニトロイミダゾール誘導体の製法 | |
KR20090099237A (ko) | 구리 촉매를 이용한 2-술포닐이미노인돌린 제조방법 | |
EP1179532A1 (en) | Process for the production of indole derivatives and intermediates therefor | |
WO2011013635A1 (ja) | 3位に脱離基を有する2-フルオロプロピルアミン保護体またはn-アルキル-2-フルオロプロピルアミン保護体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2008503761 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007224066 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007707942 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007224066 Country of ref document: AU Date of ref document: 20070202 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780007796.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7558/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2645154 Country of ref document: CA Ref document number: 12224849 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087023532 Country of ref document: KR |